squibb – Page 4

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.

Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer

9 months ago talkbio0Tagged Combined Modality Therapy, first-line, LAG-3/PD-1, Malignant neoplasm of lung, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy

Bristol Myers Terminates Partnership with Immatics on Bispecific Cancer Drug After $150M Investment

9 months ago talkbio0Tagged bispecific cancer, Immatics, Investments, Myers, partnership termination, squibb

Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment

Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial

9 months ago talkbio0Tagged AbbVie, Antipsychotic Agents, Biosciences, Emraclidine, KarXT, Muscarinic Acetylcholine Receptor, Myers, NBI-1117568, Neurocrine, Schizophrenia, squibb

Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics

FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

10 months ago talkbio0Tagged Cancer Therapeutic Procedure, Claims, Effectiveness, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, non-small-cell lung cancer, squibb, United States Food and Drug Administration

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

Biopharma Layoff Tracker 2024: Precigen, Sumitomo, BMS and More Cut Staff

10 months ago talkbio0Tagged Biopharma layoffs, Industry, Myers, pharmaceutical companies, Precigen, restructuring, squibb, Sumitomo

biopharma layoffs, Precigen, Sumitomo, Bristol Myers Squibb, biotech industry, job cuts, restructuring, pharmaceutical companies

Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus

10 months ago talkbio0Tagged Agenus, Dosage Forms, licensing agreement, Myers, squibb, TIGIT gene

Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal